Increased Survival Time With SS-31 After Prolonged Cardiac Arrest in Rats
Heart Lung Circ
© 2018 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Cardiac arrest is one of the leading causes of death with a very high mortality rate. No therapeutic drug that can be administered during resuscitation has been reported. Mitochondrial dysfunction is believed to play an important role for the pathogenesis of cardiac arrest. SS-31, a tetra-peptide, has been shown to protect mitochondria from ischaemia/reperfusion injury. Therefore, we tested whether SS-31 improves rat survival after prolonged cardiac arrest.Rats were randomised into two groups. After 25. minutes of asphyxia-induced cardiac arrest, rats were resuscitated with or without SS-31 using cardiopulmonary bypass resuscitation. Rat survival was followed for additional 4.5. hours using haemodynamic monitoring. The blood gas was analysed for surviving rats at multiple time points.After 5. hours, 5 of 10 rats survived in the SS-31 group whereas only 1 of 10 rats survived in the control group (p = 0.026). At 90. minutes after resuscitation, the blood lactate level in the SS-31 treated rats (4.29. ±. 2.5. mmol/L) was significantly lower than in control rats (7.36. ±. 3.1. mmol/L, p = 0.026), suggesting mitochondrial aerobic respiration was improved with SS-31 treatment. Overall, our data show the potential of SS-31 as a novel therapeutic in cardiac arrest.
Faculty; Northwell Researcher
School of Medicine; Northwell Health